All posts by imreal

PET Prostate Scan Volumes See Robust Growth in 2022 according to IMV’s 2023 PET Market Summary Report


IMV’s 2023 PET Market Summary Report explores market trends in U.S. hospitals and imaging centers, including procedure volume, manufacture-installed base features and share, the use of OEM vs. third-party service providers, purchase plans, brand loyalty, radiopharmaceutical usage and site operations characteristics. The report was published in March 2023 and is based on responses from 386 radiology/departmental administrators and clinicians who participated in IMV’s nationwide survey from August 2021-September 2022. Vendors covered in this report include Bracco, Canon, Cardinal Health, GEHC, Jubilant, Philips, Siemens and SOFIE. The finding summaries follow.

PET prostate scan volumes increased 46% year-over-year, showing an increase of 3 percentage points to 9% of the overall procedure mix by study type, according to the newly published IMV 2023 PET Market Summary Report.

After a 12.2% increase in overall PET scan volume in 2021, PET scan volume remained flat year-over-year in 2022. However, the change in volume of PET scans varied by site type, with less than 400 bed hospitals having a 25% increase in scan volume, non-hospital sites seeing a 10.9% decrease and 400+ bed hospitals remaining flat in 2022.

Looking ahead, 47% of PET imaging sites anticipate their scan volumes will increase over the next 12 months, 44% volumes to stay the same and 1% anticipate a decrease.

Pertaining to radiopharmaceutical usage, 82% of PET scans used F-18-FDG, 7% used Rb-82 and all other agents made up the remaining 11%.

In 2022, 30% of sites were considering the purchase of a PET scanner over the next three years. Of planned system purchases in 2022, 92% will be equipped with a digital detector. The top OEMs being considered for future PET system purchases are Siemens with 64% of mentions, GEHC with 54%, Philips with 8%, Canon with 4% and United Imaging with 2%.

Regarding patient wait times for non-emergency outpatient PET scans, the overall median wait time is 6 days, with 29% of sites having a median wait time of less than 3 days. Independent PET sites have the shortest median wait time of 3 days, and 400+ bed hospitals, less than 200 bed hospitals and hospital-owned PET centers have the longest, with a median wait time of 7 days.

Want to share your knowledge of medical imaging? Click here to sign up for the IMV Survey Panel today.

For information about purchasing IMV Market Outlook Reports, visit the corporate website at https://imvinfo.com/ or call 703-778-3080 ext. 1033 to speak with a representative. In addition to the report, all purchases will include a complimentary recording of an executive summary presentation of findings conducted by IMV’s Senior Program Manager.

Disclosure: IMV Medical Information Division is a sister company of AuntMinnie.com.

Share article on social media or email:

Proem Behavioral Health to Exhibit at Rx and Illicit Drug Summit


Proem Behavioral Health will meet with attendees of the Rx and Illicit Drug Summit on April 10-12 to discuss how the company’s workflow engine helps practitioners treat SUD and mental illness.

“We have designed the Proem solution to make it easier for SUD providers to track, trend and measure patient outcomes and share vital progress reports with their patients,” said Proem CEO John Letter.

Proem Behavioral Health, developer of the evidence-based clinical workflow software engine that helps substance use disorder (SUD) clinics assess SUDs and mental illness to help achieve verifiable outcomes, invites attendees of the 2023 Rx and Illicit Drug Summit in Atlanta on April 10-12 to visit Proem Booth 142.

The intelligent workflow engine from Proem easily integrates into the workflow of SUD practitioners to simultaneously assess SUDs and the most common adult and pediatric mental disorders. This allows practitioners to effectively identify, diagnose, treat and monitor SUD and the underlying mental health disorders that often cause people to self-medicate with drugs and/or alcohol.

By using Proem, providers are more likely to make the right diagnosis the first time. For SUD practitioners, this gives peace of mind that they have a comprehensive picture of their patient so they can treat the whole person, not just the drug or alcohol dependence, and provide the proof of progress that’s essential for keeping patients engaged in their treatment and on a path to recovery.

Key features of the Proem solution include the following:

  • Evidence-based measurements and scales designed to fit seamlessly within a SUD practitioner’s existing workflow.
  • Multi-dimensional screeners and assessments that evaluate multiple mental illnesses to identify root causes of substance use.
  • Outcome and severity measurement tools that help practitioners adjust treatments when they are not working or continue those that are working.
  • Data collected at every step of the process to provide the documentation needed to demonstrate verifiable patient outcomes to providers, patients and payers.

“At Proem, we understand the challenges SUD clinics and practitioners face when working to help their patients overcome addiction and take better control of their lives,” said Proem CEO John Letter. “We have designed the Proem solution to make it easier for SUD providers to track, trend and measure patient outcomes and share vital progress reports with their patients. The Rx and Illicit Drug Summit meeting provides us an opportunity to show attendees how our solution is helping clinics and practitioners support individuals with SUD and mental illness and why we believe ‘healthy minds start with Proem.'”

ABOUT PROEM BEHAVIORAL HEALTH

Proem Behavioral Health provides the premier clinical workflow software engine that helps substance use disorder clinics, behavioral health providers and research organizations efficiently and accurately screen, test, and measure treatment success for those suffering from mental illness. Proem is the exclusive digital licensee worldwide of gold-standard, evidence-based screening solutions, structured interviews and post-diagnosis severity measurement scales to monitor patient outcomes. To learn more, visit proemhealth.com and follow Proem on LinkedIn and Twitter.

Share article on social media or email:



CS Analytical to Host Laboratory Tours and Client Meeting Program During NYC Interphex Week


News Image

While we routinely host client audits, the fact that Intephex is just around the corner enables us an opportunity to offer client tours and meetings for those contacts that are not local to our facility.

CS Analytical Laboratory, the world’s only cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to package and container testing for the pharmaceutical, biotechnology, and medical device industries, in conjunction with the New York Interphex Show scheduled for April 25th through April 27th, will host an open house and laboratory tour program for visiting clients. Clients coming to the New York Metropolitan area for Interphex will have the opportunity to schedule meeting time slots at the CS Analytical Laboratory. With a state of the art laboratory that features the most up to date instrumentation and electronic quality system processes, Interphex week, provides an ideal setting for clients to see in person the CS Analytical facility and meet its team members to discuss current and future container and package system testing needs.

“There is no other contract service provider within the FDA regulated community that is exclusively dedicated to container and package system qualification testing,” commented Sandra Cincotta, Director of Quality. “We have built out a laboratory facility that is designed to meet all USP and EP routine qualification testing requirements, can develop and validate methods specific to all of the current USP 1207 technologies for container integrity testing, and implemented a custom designed electronic quality system. While we routinely host client audits, the fact that Intephex is just around the corner enables us an opportunity to offer client tours and meetings for those contacts that are not local to our facility.”

Intephex will take place in New York City at the Jacob Javits Convention Center located on 34th street on the West Side of Manhattan. CS Analytical is located 12.6 miles due west through the Lincoln Tunnel, directly off Route 3 West. The drive from the show to the CS Analytical Laboratory will only take approximately 20-25 minutes. Onsite meetings at Interphex and Laboratory Tours may be may be pre-scheduled using the following link: https://engage.csanalytical.com/interphex

About CS Analytical Laboratory

The world’s only cGMP, FDA-registered contract laboratory exclusively designed and dedicated to container testing for the pharmaceutical, biotechnology, and medical device industries, the CS Analytical Team includes world-leading experts and thought-leaders on FDA and EU regulatory expectations and USP and EP primary package testing requirements inclusive of container closure integrity (CCI) testing (CCIT). Test services include CCI method development, validation, and analysis, USP/EP/JP physical and physicochemical testing, and Comprehensive and Complementary services for all common or unique primary packaging components and systems inclusive of glass, plastic, elastomeric, and more. CS Analytical is the single source to ensure a regulated industry product-package system meets strict, complex, and ever-changing regulatory requirements.

Share article on social media or email:

SAC Health Announces Major Grant to Expand Services to Help Improve Quality of Life for Inland Empire Residents


SAC Health Building and San Bernardino Campus

SAC Health – San Bernardino Campus

We have seen first-hand, how effective it is in helping individuals who have the most complex healthcare needs. Thanks to the California Department of Health Care Services and IEHP, SAC Health will be able to expand access to Enhanced Care Management for our patients. – Jason Lohr, CEO

SAC Health announced the award of a $2.139 million grant from the California Department of Health Care Services that will help increase the healthcare management of those who are in most need throughout the region. Through the following programs: ​California Advancing and​Innovating Medi-Cal (CalAIM) Initiative; Providing Access and Transforming Health (PATH); Capacity and Infrastructure Transition, Expansion and Development (CITED) Initiative, SAC Health will increase the number of Enhanced Care Management teams by four, resulting in 10 teams, serving over 2,000 patients at any given time.

Enhanced Care Management is a whole-person, interdisciplinary approach to care that addresses the clinical and non-clinical needs of eligible Medi-Cal Members who have the most complex medical and social needs. It allows for a systematic coordination of services and comprehensive care management that is personal, community-based, and multi-disciplinary. SAC Health implemented Enhanced Care Management in (given year) through funding from Inland Empire Health Plan (IEHP).

“SAC Health implemented Enhanced Care Management in 2017 with the financial support of IEHP,” notes Jason Lohr, MD, CEO of SAC Health. “We have seen first-hand, how effective it is in helping individuals who have the most complex healthcare needs. Thanks to the California Department of Health Care Services and IEHP, SAC Health will be able to expand access to Enhanced Care Management for our patients.”

SAC Health is a Federally Qualified Health Center with twelve locations throughout the Inland Empire. Serving over 50,000 patients in 2022, with over 97 percent being at or below 200 percent of the Federal Poverty Line, SAC Health is a safety-net clinic providing high quality patient-centered care throughout the region.

About SAC Health

SAC Health is the largest specialty-based and teaching health center (THC) Federally Qualified Health Center (FQHC) in the nation. SAC Health provides comprehensive services to underserved areas and populations including Medi-Cal and Medicare patients. SAC Health is recognized as a Level-3 Patient-Centered Medical Home by the National Committee for Quality Assurance (NCQA) and has over 100 community partnerships that enable the health to provide whole-person care to all its patients. SAC Health provides care in 12 locations, along with a mobile clinic, in San Bernardino and Riverside counties, including services in family medicine; pediatrics and pediatric specialties; obstetrics and gynecology, internal medicine and medical specialties; family dentistry; behavioral health; surgical specialties and more. More information on how to become a patient at SAC Health is available online at sachealth.org.

Share article on social media or email:

iuvo BioScience Hires Industry Executive to Lead Commercial Organization


Sanjeev will be welcomed into a fast-paced ophthalmology business that span services from pre-clinical, scientific consulting and clinical development, where his contribution will be essential to our continued growth.

iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to biopharmaceutical and medical device customers, today announced it has hired Sanjeev Ganatra, MBA, as their Chief Commercial Officer. This hire demonstrates iuvo’s continued commitment to client service, differentiated expertise, and investment in the business to support the company’s growth trajectory.

Ganatra is a well-established operational and business executive who brings years of experience in sales, marketing, business and corporate development both in pharma service companies as well as commercial organizations. Ganatra spent his early years in pharmaceutical and medical device development organizations before moving into the pharma services business. He spent three years with a global ophthalmic CRO, and most recently was the SVP of Sales and Marketing and Global Head of Ophthalmology at CBCC Global Research.

Ganatra is excited about joining the iuvo team, stating, “The journey that has led iuvo to its current level of success is attributed to the combination of a great team, excellent service, and collaborative clients. My goal is to help further build on this platform, creating new opportunities for our team to demonstrate their talent and for our clients to have a comprehensive partner for their development needs.”

Daniel Spasic, Board Chair of iuvo BioScience, offered his welcome as well, “We’ve all been impressed by Sanjeev’s accomplishments in sales and customer service, as well as his deep understanding of operational aspects in executing ophthalmology trials. He will be welcomed into a fast-paced ophthalmology business that span services from pre-clinical, scientific consulting and clinical development, where his contribution will be essential to our continued growth.”

Ben Burton, CEO of iuvo BioScience, provided these final comments, “As we enter the next phase of our company, Sanjeev will play an important role in our PROTM (Partner Research Organization) Model as we continue to serve clients across the globe. Sanjeev’s demonstrated expertise in client service is a perfect cultural fit for our team, and his business acumen and performance track record will create value immediately for iuvo BioScience. We are excited to have Sanjeev on-board.”

About iuvo BioScience

Headquartered in Rochester, NY, iuvo BioScience is a highly specialized provider of preclinical, clinical, and consulting services to biotech and medical device customers. The company’s facility features laboratories for analytical chemistry, microbiology, pharmacology, and toxicology, as well as an on-site AAALAC-accredited vivarium to support preclinical testing. Through the company’s Oculos Clinical Research subsidiary, iuvo provides a suite of clinical trial services including clinical trial design, regulatory, biometrics, pharmacovigilance, project and site management. Under the Lumino Advisors brand, the company also has an end-to-end scientific consulting offering spanning from regulatory strategy, dossier development, preclinical and CMC consulting and strategic planning through trial execution and regulatory submission. Additional information about iuvo is available at http://www.iuvobioscience.com

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit http://www.ampersandcapital.com or follow us on LinkedIN at https://www.linkedin.com/company/ampersand-capital-partners/.

Share article on social media or email:

NexCore Group breaks ground on Intermountain Health Aurora Crossroads Campus Medical Office Building


Officials of NexCore Group and Intermountain Health break ground

Officials of NexCore Group and Intermountain Health were on hand for the Mar. 21st ground breaking event.

The Aurora Crossroads Medical Campus will become the epicenter of healthcare in the area as part of Intermountain Health’s robust ambulatory care network strategy.

Denver-based NexCore Group, a nationally recognized healthcare real estate investment and development company, broke ground on a new medical office building for Intermountain Health (formerly SCL Health) on their Aurora Crossroads campus March 21, 2023. The three-story, 85,000 square foot facility is conveniently located at the intersection of E-470 and I-70 in north Aurora and is projected to open in the second quarter of 2024.

“NexCore is excited to provide a facility designed to provide quality, comprehensive care in this fast-growing area,” said Tom Kelly, Senior Vice President, Real Estate Development for NexCore. “The Aurora Crossroads Medical Campus will become the epicenter of healthcare in the area as part of Intermountain Health’s robust ambulatory care network strategy.”

The new medical office building will increase patient access to care in the area, housing comprehensive services including 8 primary care physicians, diagnostic imaging, lab, an ambulatory surgery center, an endoscopy center, and a variety of specialists such as OB/GYN, Orthopedics, General Surgery, and Cardiology. Plans also include proposed connectivity to the future hospital.

NexCore was selected by Intermountain Health through a competitive process to execute on their vision to expand into the Aurora market, providing patients with a differentiated, integrated care experience. “This is the perfect opportunity for NexCore to deliver a healthcare facility that brings excellence, convenience and comprehensive care to the community,” remarks Todd Varney, NexCore’s Chief Development Officer and Managing Partner. “At NexCore we build better outcomes – better outcomes for our health system providers, patients, and the surrounding community – and there’s no place we would rather deliver on that promise than in the area surrounding our headquarters.”

For a video of the Intermountain Health Aurora Crossroads Medical Office Building ground break please visit: https://vimeo.com/nexcoregroup/imhauroragb

Limited space is still available for lease to complementary independent physicians. For leasing information, please contact Kristen Neumann at kristen.neumann@nexcoregroup.com or 303-710-1909.

For more information or for comment, please contact Kirstin Barbour at kirstin.barbour@nexcoregroup.com or 303-501-6713.

NexCore Group LLC is a national healthcare real estate investment and development company that focuses on acquiring, developing, owning, and managing purpose-built facilities for healthcare, senior living, and science and technology. Since its founding in 2004, NexCore has successfully completed over $5.5 billion in real estate transactions throughout 25 states, developed and acquired over 15.2 million square feet of healthcare, science, and senior living communities, and currently manages over $3.3 billion in assets spanning 7.6 million square feet. NexCore is headquartered in Denver, with regional offices in Bethesda, Charlotte, Dallas, Detroit, Houston, Indianapolis, Los Angeles, Orlando, Phoenix, and Seattle.

Share article on social media or email:

RCH Solutions To Host Networking Event at Bio-IT World 2023


We look forward to sharing our knowledge and experiences with the attendees of Bio-IT World 2023, an event that provides an excellent opportunity for us to connect with our colleagues and industry peers, and showcase how RCH can help organizations overcome their scientific computing challenges.

RCH Solutions, Inc., a leading provider of scientific computing Consulting, Professional, and Managed Services exclusively for Life Sciences teams, has announced its participation in the 22nd annual Bio-IT World Conference and Expo, May 16th – 18th at the Hynes Convention Center in Boston, MA. The long-standing event will bring together scientists, researchers, and technology experts from the Life Sciences space to discuss the latest IT and technology innovations in drug research, discovery and development.

“We are thrilled to participate in Bio-IT World 2023, an important industry event that has always been a valuable opportunity for face-to-face collaboration in the Life Sciences,” said Michael Riener, CEO of RCH Solutions. “Our team is excited to again connect with industry colleagues and friends—old and new— and share how our science-centered Bio-IT solutions can help organizations address their complex compute challenges.”

To drive additional connection and collaboration, RCH Solutions and long-time partner 20/15 Visioneers will host an evening of cocktails and hors d’oeuvres at their private event, ‘Cocktails and Computing’, following day 1 of the Bio-IT World Event & Expo. The event will provide a valuable opportunity to connect with peers and discuss the latest trends and opportunities driving Bio-IT success within companies large and small.

Where to Connect with RCH Solutions at Bio-IT World 2023

At the event, you can find RCH at booth 911, where their team will be on-hand to share how it’s driving successful customer outcomes—from project inception through execution—by way of its comprehensive suite of scientific, Cloud and technical computing solutions, including their unique Sci-T Consulting, Professional and Managed Services support offerings. For more than 30 years, the company’s services have helped start-up, emerging and global Life Science organizations design, build and tune optimized compute environments that enable R&D teams to accelerate innovation in drug discovery and development.

“We look forward to sharing our knowledge and experiences with the attendees of Bio-IT World 2023,” added Riener. “This event provides an excellent opportunity for us to connect with our colleagues and industry peers, and showcase how RCH can help organizations optimize their environments to achieve their goals.”

RCH’s sponsorship and strong presence at Bio-IT World this year, combined with their recently established MassBio membership demonstrates their continued Boston-area focus, and their rapidly growing demand as an industry leading Bio-IT provider in the Life Sciences.

To learn more about RCH Solutions and its unmatched suite of scientific computing solutions, find their team at booth 911 and register for their private event, ‘Cocktails and Computing’ while space lasts.

Contact:

Melissa Thomas

215-499-9788

media@rchsolutions.com

About RCH Solutions:

RCH Solutions (RCH) is a global provider of Bio-IT expertise, helping Life Sciences and Healthcare companies of all sizes clear the path to discovery. For more than 30 years, RCH has provided focused experience and unmatched specialization designing and deploying cross-functional IT strategies, supporting R&D infrastructure, and offering workflow best practices that solve enterprise and scientific computing challenges. Learn more at http://www.rchsolutions.com

Share article on social media or email:

Optimized performance and flexibility in a market-proven design


News Image

– Brand new PDA family of enterprise-class mobile computers, designed for customers in retail, warehousing, transportation & logistics, and manufacturing;

  • Flexible choice between Wi-Fi only or Wi-Fi/Cellular models;
  • Enhanced processing capabilities, it boasts the latest Android 11 OS along with the benefits of Google Mobile Services and it is certified as an Android™ Enterprise Recommended device;
  • Enhanced usability and performance with a 5-inch touch screen and fast 2.3GHz octa-core processor;
  • Advanced battery management system and ultra-reliable wireless charging technology that minimizes maintenance and provides a hassle-free charging experience;
  • Industrial High-End barcode scanner with optimized DOF and enhanced performance in dark warehouses; paired with Datalogic’s exclusive Green Spot Technology for improved efficiencies and good-read visual feedback.


Bologna, March 31, 2023. Datalogic, a global leader in the automatic data capture and factory automation markets, has just unleashed its latest and greatest product – the Memor™ 11 family of mobile computers! This cutting-edge addition to the prestigious Memor Series is designed to offer unparalleled flexibility for today’s mobile workforce. Boasting an up-to-date operating system and enhanced processing capabilities, the Memor 11 family delivers superior scanning performance and all-around efficiency. It is the perfect solution for those who need versatility for in-store retail operations and inventory management; for inbound/outbound warehouse logistics, manufacturing traceability and quality control; and in transportation & logistics applications. The Memor 11 family fulfills all of your requirements to the highest levels.

Choose between Wi-Fi only or Wi-Fi/Cellular models, depending on your use case, and always stay connected. The Memor 11 family runs seamlessly in indoor premises or when combined with outdoor operations and field mobility.

Offering a rugged design in a slim and compact form factor, the Memor 11 family is enterprise-ready and offers greater resilience to withstand more drops than most comparable devices. The bright 5-inch touch display enhances the user experience, while its advanced processing platform ensures top performance in popular applications, all while extending product life. The speedy 2.3 GHz Octa-Core processor allows the Memor 11 to simultaneously run multiple mobile applications at significantly faster speeds, resulting in improved response times.

Datalogic has a reputation for investing in R&D, and the Memor 11 family will receive even greater development emphasis, keeping it at the cutting edge of industrial PDA technology.

“The Memor 11 family with a choice of Wi-Fi and Wi-Fi/Cellular models, offers a perfect balance of affordability, performance, and ruggedness for retail, transportation and logistics, warehouse, and manufacturing customers. We are excited to introduce this new family of mobile computers in a market-proven design that lowers the total cost of ownership while delivering improved performance and longevity,” states Mangaraju Vuppala, Mobile Computers Product Marketing Manager Leader.

The inclusion of an advanced battery management system and ultra-reliable wireless charging technology for contactless charging helps minimize maintenance for your Memor 11 and provides a hassle-free charging experience. The long-lasting swappable battery and built-in SafeSwap™ technology guarantee uninterrupted continuity. Smart Battery Management provides several configurable options to optimize battery profile according to usage, extending battery life by up to 20%.

Experience enhanced reading performance in dark warehouses or outdoor environments with the industrial-grade barcode scanner that is ideal for the Memor 11. Coupled with Datalogic’s exclusive Green Spot Technology, it provides visible good-read feedback in extreme lighting conditions or for when visual feedback is required in a designated quiet area, increasing accuracy and efficiency.

The rugged Memor 11 family has been certified as an Android™ Enterprise Recommended device, ensuring the enhanced security and privacy settings of Android™ 11 with the benefits of Google Mobile Services.

Plus, with Datalogic’s world-class service coverage of EASEOFCARE and Datalogic Shield, you’ll receive years of protection, extending the value of your device investment.

Expand efficiencies in the field by easily pairing the Memor 11 devices with Datalogic’s RFID Sled for efficient collection of large volumes of RFID information and via Bluetooth® connectivity with Datalogic’s HandScanner™ for hands-free reading in scan-intensive applications, such as in warehousing.

The Memor 11 family is fully backward compatible with all accessories for existing Memor 10 mobile computers, helping companies save on upgrade costs and reduce the total cost of ownership. Choose the Memor 11 family of mobile computers for unparalleled efficiency and power, now and for the future!

Share article on social media or email:

hyperCORE International Appoints Carlos E. Orantes as New Chairman of Executive Board


Carlos E. Orantes portrait

Carlos E. Orantes Appointed Chairman of hyperCORE Executive Board

“I am honored to be taking on the role of Chairman of hyperCORE, where I will continue working closely with our super network alliance partners to continue making our value proposition to Sponsors and CROs a very compelling one.” – Carlos E. Orantes, CEO of Alcanza Clinical Research

hyperCORE International has announced the appointment of Carlos E. Orantes, CEO of Alcanza Clinical Research, as Chairman of the hyperCORE Executive Leadership Board. Effective April 2023, Orantes succeeds Mark Lacy, who has served as Chairman since the super network’s inception in 2019.

“I am honored to be taking on the role of Chairman of hyperCORE, where I will continue working closely with our super network alliance partners to continue making our value proposition to Sponsors and CROs a very compelling one,” said Orantes. “The passion for delivering strong clinical research is palpable amongst all my hyperCORE colleagues, which will make this role extremely fulfilling for me both personally and professionally.”

Orantes, who has worked in drug development for almost 30 years, continues to serve as CEO of Alcanza Clinical Research. His efforts have been focused on building capable teams and leading them through transformations at several successful small to large companies, privately and publicly held. He is passionate about empowering team members and holding to a high standard of delivering on commitments.

“hyperCORE takes great pride in having each of its members actively supporting this wonderful super network,” said Karri Venn, CEO of hyperCORE and COO at Centricity Research. “Carlos Orantes is stepping into this role as one of the newer members of hyperCORE and is eager to do his part to support the continued growth and objectives we have set out for our group. I am incredibly excited to work with him and appreciate the passion he is bringing to this position.”

“It has been an absolute honor working with Mark Lacy as Chairman for the past two years,” Venn continued, “and Benchmark Research will continue to be a part of the hyperCORE network.” Lacy is the Founder and CEO of Benchmark Research, a growing and dynamic network of quality clinical research sites throughout the United States that is also a founding alliance partner of hyperCORE International.

Share article on social media or email:

How Humanized Mice Studies Can Accelerate Preclinical Research in Infectious Diseases, Upcoming Webinar Hosted by Xtalks


HIV/AIDS and malaria remain major public health problems worldwide.

The World Health Organization (WHO) reports that: 2.3 million people living with HIV in the WHO European Region have been infected with the virus over the past 40 years; In 2021, nearly 80 percent of all deaths were due to malaria in the WHO African Region.

These numbers indicate that HIV/AIDS and malaria remain major public health problems worldwide.

In this webinar, attendees will learn about the strategic potential of humanized mice in the search for treatments for these infections.

In the first part, featured speaker Dr. Sebastien Tabruyn, will discuss how the human immune system responds to infection in a humanized CD34-NCG mouse model, the preclinical analysis toolkit of the HIV platform and how the humanized model allows for the evaluation of drug candidates, especially for infectious diseases.

In the second part, featured speaker Dr. Iñigo Angulo-Barturen, will discuss the humanized Plasmodium falciparum mouse model for the study of human malaria and in vivo evaluation of new antimalarial drugs. He will present the characteristics of the humanized P. falciparum asexual blood stage (ABS) mouse models available at the drug discovery company TAD, their use as tools to study the development of resistance during suboptimal treatment regimens and the efficacy of monoclonal antibodies and drugs against susceptible and resistant strains.

Register today to find out how humanized mice models can accelerate preclinical studies in infectious diseases such as malaria and HIV.

Join Dr. Sebastien Tabruyn, PhD CSO, TransCure bioServices; and Iñigo Angulo-Barturen, PhD, CEO, The Art of Discovery SL, for the live webinar on Tuesday, April 25, 2023, at 11am EDT (5pm CEST/EU-Central).

For more information, or to register for this event, visit How Humanized Mice Studies Can Accelerate Preclinical Research in Infectious Diseases.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email: